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TRENDS IN COMPARATIVE EFFECTIVENESS OF TOP 20 HIGHEST 
SELLING DRUGS
Aggarwal S, White N, Stevens C
PAREXEL INTERNATIONAL, Bethesda, MD, USA
OBJECTIVES: The recently made coverage decisions by UK’s NICE, Scotland’s SMC 
and the allocation of $1.1 Billion for comparative effectiveness research by the United 
States, are strong indicators of trends in pricing and reimbursement that are likely to 
be observed in the future. To gain an additional insight into these trends, we analyzed 
the cost effectiveness studies for the top twenty highest selling drugs (^$160B world-
wide sales) METHODS: Drugs were categorized as primary care, specialty, small 
molecules, biologics, therapy areas and availability of generic alternatives. Cost effec-
tiveness Ratios (CERs) published in peer-reviewed journals and technology assess-
ments conducted by payers were used for this analysis. RESULTS: There is a large 
variability in CERs for same drugs for different indications, in some cases also varying 
by biomarkers. Primary care drugs had lower and less variable CERs than specialty 
drugs. For example, CERs for clopidogrel range from $13,000 to $32,000, whereas 
for bevacizumab, it ranged from $125,000 to $350,000. Most striking was the CER 
for epotein alpha, which was ^$55,000 for Hb target levels of 11.0–12.0 g, but 
increased dramatically to $613,015 for target Hb of 12.0–12.5 g. Our analysis of 
‘generic alternatives’ and the ‘new clinical evidence’ shows that previously deemed 
cost effective drugs could be re-assessed as being not cost effective when generics or 
new branded drugs with comparable efﬁcacy become available (e.g. CATIE trial data 
for quetiapine). This would play a major role in the future, as more payers, including 
the US public payer CMS, explore ways to design a continuum in the coverage decision 
making process; implying that updated cost effectiveness ratios could change previ-
ously established coverage policies. CONCLUSIONS: This analysis shows the range, 
variability and methods used for calculation of ICER values for these high budget 
impact drugs and provides lessons for executives and policy makers.
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PRICING AND REIMBURSEMENT (P&R) IN BRIC COUNTRIES
Shepelev J, Richard L
GfK Healthcare, London, UK
OBJECTIVES: To review the procedure and requirements for P&R of pharmaceuticals 
in Brazil, Russia, India and China. METHODS: A review was conducted of the ofﬁcial 
websites of governmental and public health institutions in the countries of interest. 
This review was complemented by interviews with key stakeholders in the respective 
countries. RESULTS: Free pricing of pharmaceuticals exist in general terms in Russia 
and India. In India, free pricing applies to non-scheduled drugs and pricing restrictions 
may be extended to drugs on the National Essential Medicines List. In China, prices 
are ﬁxed by central government; whereas in Brazil external drug pricing is used as the 
major cost-containment measure. In Brazil, hospital drugs are reimbursed if they are 
on the Essential Medicines List and expensive therapies for cancer and chronic diseases 
are provided by the Exceptional Medicines Program. Reimbursement of retail drugs 
is limited to the Popular Pharmacy Program and the majority of costs are covered out 
of pocket. Similarly, the most drugs costs are covered out of pocket in India; with 
only established generics being reimbursed. Russia saw the federal reimbursement 
system, DLO, being introduced in 2005 to provide pensioners, invalids, and patients 
suffering from chronic diseases access to new therapies. In 2008 the DLO program 
was split into two subprograms: the expensive medicines program covering seven 
indications, with the remaining drugs on the DLO list being supplied through the 
ONLS program. In China, innovative drugs are currently negotiated at local level. 
CONCLUSIONS: Although cost-containment measures seen with more traditional 
markets are prevalent in the emerging markets, these markets are still undergoing sig-
niﬁcant changes in their P&R frameworks. Thus, as these markets develop their pro-
cesses further, it will be necessary not only to consider P&R in the context of 
conventional wisdoms but also the political, social and cultural norms underpinning 
these systems.
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POSITIVE DRUG LIST IN BULGARIA—5 YEARS LATER
Ivanova AD1, Petrova GI1, Benisheva—Dimitrova TV2
1Medical University, Faculty of Pharmacy, Soﬁa, Bulgaria, 2Medical University Soﬁa, Faculty of 
Public Health, Soﬁa, Bulgaria
OBJECTIVES: To compare the regulatory framework and the structure of the Positive 
Drug Lists (PDL) in Bulgaria issued in 2003 and 2009.  METHODS: Comparative 
legislation analysis was applied towards the requirements of the newly adopted regula-
tion on PDL in 2008 with the regulation in 2003. It was analysed the requirement to  
the applicants, including the pharmacoeconomic evidences, selection procedure and        
the structure of the PDL. RESULTS: Main changes in PDL regulation are the follow-
ing. In 2003 PDL the medicines were selected according to their innovativeness in one 
list under INN. In 2008 PDL medicines were separated in 4 lists according to the   
ﬁnancing sources—Health Insurance, Hospital, Governmental budget and National       
Health programs. The criteria for the medicines evaluation were increased (efﬁcacy, 
effectiveness, safety and pharmacoeconomic) and detailed in the new regulation. The  
PDL Committee is deciding both reimbursement status and level. The reimbursement 
level is deﬁned on the basis of the international comparison with reimbursement levels 
in 7 reference countries calculated as lowest cost per DDD per unit. The changes in   
the structure of the PDL are the following. In 2003 there were list A with 625 INNs 
and list B with trade names that were updated on a yearly basis. In 2009 the four 
separated lists include 575 INNs presented with their trade names and dosage forms      
together. Reimbursement list 1 include 289 INNs, list 2 (518 INNs), list 3 (101 INNs) 
and list 4–59 INNs. Lots of INNs in all lists are overlapping. Also near 50 combina-
tions are presented in the PDL. CONCLUSIONS: The new PDL includes less INNs 
as a total number and lots are overlapping between the lists. No National pharmac-  
oeconomic guideline exists both for the PDL committee and manufacturers and thus 
no evidences for the inﬂuence of pharmacoeconomics exist.      
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FREE BUT VALUABLE: THE ECONOMIC SIGNIFICANCE OF SERVICES 
PROVIDED BY PORTUGUESE PHARMACIES
Gouveia M1, Machado F1, Mendes Z2
1FCEE, Universidade Católica Portuguesa, Lisbon, Portugal, 2CEFAR-Center for Health 
Evaluation Studies, Lisbon, Portugal
OBJECTIVES: Besides dispensing medicines, pharmacies render other services includ-
ing advice on health problems and on the best use of medicines; detecting problems 
in patients’ medications; counseling on nutrition, etc. The majority of these services 
is free. Up to now, the volume of these services in Portugal were unknown. This paper 
presents 2008 estimates for the volume of pharmacy interventions and their economic 
value. METHODS: The data came from two 2008 surveys. A pharmacy survey was 
designed to estimate the volume and cost of the free interventions in community 
pharmacies in Portugal. In a general population survey, respondents answered a set 
of questions (choice experiments) designed to elicit their willingness to pay for a few 
typical services provided for free at community pharmacies. RESULTS: We estimate 
a total of 38.8 million free pharmacy interventions in 2008, 3.7 interventions per 
inhabitant. The top three pharmacy interventions were advice on non-prescription 
medicines, advice on prescription-only medicines and counseling related to point-of-
care measurements and monitoring (cholesterol, pregnancy, etc.) and they used 2.8 
million hours of work, about 13% of the total hours of work, at a cost of a54 million. 
This cost was equivalent to 20% of the pharmacies’ gross income. We estimated the 
willingness to pay for the three main pharmacy interventions by conjoint analysis. The 
aggregate value of the services provided was estimated at a76.5 million. The net value, 
from society’s perspective, for the three interventions was estimated to be a51 million. 
CONCLUSIONS: We found the volume of services provided at no charge to be sig-
niﬁcant, as were the resulting pharmacies’ costs. The beneﬁts to consumers were even 
larger generating a substantial net beneﬁt to society.
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CONSENSUS OF KEY DECISION MAKERS AND EXPERTS ON THE 
PRESENT AND FUTURE ON THE ASSESSMENT OF HEALTH 
TECHNOLOGIES IN SPAIN
Paz S1, Lizan L2, Rodriguez JM3, Anton E3
1Outcomes’10 Research Group, Castellon, Castellon, Spain, 2Jaume I University, Castellon, 
Spain, 3Medtronic Iberia, Madrid, Spain
OBJECTIVES: Mechanisms for assessing health technologies (HT) have gone through 
major regulatory changes over the last ﬁve years in Spain. This study aims to determine 
the consensus level amongst decision makers and experts on the present and future of      
health technologies’ assessment. METHODS: This is the second part of a two-phase 
study. A sample of participants and experts in HT evaluation was invited to participate 
on a two-round Delphi consultation (phase 2) about the most relevant and controver-
sial issues identiﬁed in phase I. The present situation as well as desirable (D) and fea-          
sible (P) feature scenarios were considered. Consensus was reached when given 
statements were scored 7.5 or higher by 75% or more of the participants. RESULTS: 
Decision makers (n  16) and experts (n     8) participated in the study (mean involve-      
ment length in HT assessment: 12.4 [SD: 7.7] years). Present: Consensus was reached 
on that 1) the absence of established mechanisms to set priorities and deﬁne needs 
(83.3%), and the scarce political support (79.2%) explain the little inﬂuence of current        
legislation on HT implementation; 2) safety and efﬁcacy (79.2%) are always consid-
ered to decide the implementation of HT. Coincidence of opinions existed for the poor 
deﬁnition of decision makers’ roles and responsibilities (70.8%) and the deﬁcient 
management of information between evaluation entities and decision makers (62.5%). 
Future: 1) Importance of value dossier and impact budget estimates (D: 95.8%, P: 
12.5%) to support implementation; 2) efﬁciency and cost-effectiveness data will deter-
mine decisions (D: 91.7%; P: 12.5); 3) beneﬁts for patients (D: 87.5%; P: 41.7%) and 
equity improvements (D: 91.7%; P: 16.7%) will be prioritised; 4) gains on patients’ 
satisfaction, preferences and health related quality of life (HRQL) will deserve special 
attention (D: 75%; P: 12.5%) CONCLUSIONS: An important gap exists between 
desirable (D) and feasible (P) future scenarios. Agreement upon implementation 
mechanisms is mandatory. Patient centred results become relevant.
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QUALITY ADJUSTED LIFE YEARS (QALYS) IN ECONOMIC 
EVALUATIONS OF HEALTH TECHNOLOGIES IN SPAIN: A REVIEW OF 
THE 2003–2009 LITERATURE
Lizan Tudela LV1, Paz S2, Rodriguez JM3, González P3
1Jaune I Unversity, Castellon de la Plana, Castellon, Spain, 2Outcomes’ 10 Research Group, 
Castellon, Castellon, Spain, 3Medtronic Iberia, Madrid, Spain
OBJECTIVES: To appraise economic evaluations of health technologies that included 
QALYs as an outcome measure conducted over the last seven years in Spain.   
METHODS: Economic evaluations that included QALYs as an outcome measure, 
